Hookipa Pharma Financials
This page shows Hookipa Pharma (HOOK) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Hookipa Pharma has an operating margin of -117.1%, meaning the company retains $-117 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -485.3% the prior year.
Hookipa Pharma's revenue surged 118.3% year-over-year to $43.9M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Hookipa Pharma carries a low D/E ratio of 0.61, meaning only $0.61 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 90/100, indicating a strong balance sheet with room for future borrowing.
Hookipa Pharma's current ratio of 3.27 indicates adequate short-term liquidity, earning a score of 63/100. The company can meet its near-term obligations, though with limited headroom.
While Hookipa Pharma generated -$77.0M in operating cash flow, capex of $194K consumed most of it, leaving -$77.2M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Hookipa Pharma generates a -84.9% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -90.8% the prior year.
Hookipa Pharma passes 2 of 9 financial strength tests. No profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Hookipa Pharma generates $1.77 in operating cash flow (-$77.0M OCF vs -$43.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Hookipa Pharma earns $-25727.5 in operating income for every $1 of interest expense (-$51.5M vs $2K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Hookipa Pharma generated $43.9M in revenue in fiscal year 2024. This represents an increase of 118.3% from the prior year.
Hookipa Pharma's EBITDA was -$48.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 48.3% from the prior year.
Hookipa Pharma reported -$43.5M in net income in fiscal year 2024. This represents an increase of 46.7% from the prior year.
Hookipa Pharma earned $-3.47 per diluted share (EPS) in fiscal year 2024. This represents an increase of 59.8% from the prior year.
Cash & Balance Sheet
Hookipa Pharma generated -$77.2M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 25.1% from the prior year.
Hookipa Pharma held $39.7M in cash against $0 in long-term debt as of fiscal year 2024.
Margins & Returns
Hookipa Pharma's operating margin was -117.1% in fiscal year 2024, reflecting core business profitability. This is up 368.2 percentage points from the prior year.
Hookipa Pharma's net profit margin was -99.0% in fiscal year 2024, showing the share of revenue converted to profit. This is up 306.3 percentage points from the prior year.
Hookipa Pharma's ROE was -84.9% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is up 5.8 percentage points from the prior year.
Capital Allocation
Hookipa Pharma invested $68.5M in research and development in fiscal year 2024. This represents a decrease of 20.7% from the prior year.
Hookipa Pharma invested $194K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 95.3% from the prior year.
HOOK Income Statement
| Metric | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0M+48.0% | $1.4M-71.2% | $4.7M+264.6% | $1.3M-96.5% | $36.6M+394.1% | $7.4M+7.9% | $6.9M+156.3% | $2.7M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $12.9M-1.3% | $13.0M-16.3% | $15.6M-21.2% | $19.7M-2.1% | $20.2M-4.7% | $21.2M-14.1% | $24.6M+25.0% | $19.7M |
| SG&A Expenses | $6.9M+25.4% | $5.5M-18.4% | $6.7M+70.6% | $3.9M-2.7% | $4.1M-7.3% | $4.4M-11.0% | $4.9M+10.5% | $4.4M |
| Operating Income | -$17.9M+16.7% | -$21.5M-15.1% | -$18.6M+17.0% | -$22.5M-302.2% | $11.1M+135.9% | -$30.9M-36.3% | -$22.7M-5.6% | -$21.5M |
| Interest Expense | N/A | N/A | N/A | N/A | $2K-95.9% | $49K0.0% | $49K-49.5% | $97K |
| Income Tax | $0+100.0% | -$106K | $0 | $0 | $0-100.0% | $163K | $0 | $0 |
| Net Income | -$15.4M+38.2% | -$24.9M-80.2% | -$13.8M+27.5% | -$19.1M-232.8% | $14.4M+158.0% | -$24.8M-30.2% | -$19.1M-5.8% | -$18.0M |
| EPS (Diluted) | $-1.23 | N/A | $-1.10+27.6% | $-1.52-233.3% | $1.14 | N/A | $-1.73+20.6% | $-2.18 |
HOOK Balance Sheet
| Metric | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $61.3M-25.8% | $82.5M-24.8% | $109.7M-12.2% | $125.0M-14.3% | $145.9M-9.6% | $161.3M-1.6% | $164.0M-14.2% | $191.1M |
| Current Assets | $60.1M-25.5% | $80.7M-13.4% | $93.2M-13.2% | $107.4M-19.1% | $132.7M-9.8% | $147.1M+5.5% | $139.5M-17.1% | $168.1M |
| Cash & Equivalents | $40.3M+1.5% | $39.7M-33.6% | $59.8M-22.6% | $77.2M-16.8% | $92.8M-20.8% | $117.1M+8.7% | $107.7M-20.6% | $135.6M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $545K+87.9% | $290K-10.5% | $324K+295.1% | $82K-99.2% | $10.2M+1898.4% | $511K-24.3% | $675K+164.7% | $255K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $27.2M-13.3% | $31.3M-17.4% | $37.9M-2.7% | $39.0M-5.7% | $41.3M-42.2% | $71.5M+3.7% | $69.0M-12.5% | $78.8M |
| Current Liabilities | $16.6M-32.5% | $24.7M-13.7% | $28.6M+2.6% | $27.8M-5.7% | $29.5M-29.7% | $42.0M+3.5% | $40.6M-12.3% | $46.2M |
| Long-Term Debt | N/A | N/A | N/A | N/A | $1.1M-2.4% | $1.2M+4.5% | $1.1M-3.1% | $1.2M |
| Total Equity | $34.1M-33.5% | $51.2M-28.7% | $71.8M-16.6% | $86.1M-17.7% | $104.5M+16.3% | $89.9M-5.5% | $95.1M-15.4% | $112.3M |
| Retained Earnings | -$428.2M-3.7% | -$412.8M-6.4% | -$387.8M-3.7% | -$374.0M-5.4% | -$354.9M+3.9% | -$369.3M-7.2% | -$344.4M-5.9% | -$325.4M |
HOOK Cash Flow Statement
| Metric | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $52K+100.2% | -$20.9M-19.6% | -$17.5M-21.8% | -$14.4M+40.5% | -$24.2M-115.2% | -$11.2M+53.5% | -$24.1M-24.8% | -$19.3M |
| Capital Expenditures | $20K+900.0% | $2K-93.5% | $31K-31.1% | $45K-61.2% | $116K-72.5% | $422K-86.0% | $3.0M+578.2% | $445K |
| Free Cash Flow | $32K+100.2% | -$20.9M-19.4% | -$17.5M-21.6% | -$14.4M+40.6% | -$24.3M-108.4% | -$11.6M+57.1% | -$27.1M-37.2% | -$19.8M |
| Investing Cash Flow | -$20K-900.0% | -$2K+93.5% | -$31K+31.1% | -$45K+61.2% | -$116K+72.5% | -$422K+86.0% | -$3.0M-578.2% | -$445K |
| Financing Cash Flow | N/A | $0 | $0+100.0% | -$1.1M-745.2% | -$135K-100.6% | $21.2M+3324.4% | -$659K-101.4% | $45.8M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
HOOK Financial Ratios
| Metric | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -891.9%+692.9pp | -1584.9%-1188.4pp | -396.4%+1344.5pp | -1740.9%-1771.3pp | 30.3%+447.5pp | -417.1%-87.0pp | -330.1%+471.4pp | -801.5% |
| Net Margin | -769.8%+1072.7pp | -1842.5%-1548.2pp | -294.3%+1185.9pp | -1480.2%-1519.5pp | 39.3%+374.4pp | -335.1%-57.4pp | -277.6%+394.8pp | -672.5% |
| Return on Equity | -45.3%+3.4pp | -48.7%-29.4pp | -19.3%+2.9pp | -22.2%-35.9pp | 13.8%+41.4pp | -27.6%-7.6pp | -20.1%-4.0pp | -16.0% |
| Return on Assets | -25.2%+5.0pp | -30.2%-17.6pp | -12.6%+2.7pp | -15.3%-25.1pp | 9.9%+25.2pp | -15.4%-3.8pp | -11.6%-2.2pp | -9.4% |
| Current Ratio | 3.61+0.3 | 3.27+0.0 | 3.26-0.6 | 3.86-0.6 | 4.50+1.0 | 3.50+0.1 | 3.44-0.2 | 3.64 |
| Debt-to-Equity | 0.80+0.2 | 0.61+0.1 | 0.53+0.1 | 0.45+0.4 | 0.010.0 | 0.010.0 | 0.010.0 | 0.01 |
| FCF Margin | 1.6%+1548.1pp | -1546.5%-1173.6pp | -372.9%+745.0pp | -1117.9%-1051.6pp | -66.3%+90.9pp | -157.2%+238.0pp | -395.2%+343.1pp | -738.3% |
Similar Companies
Frequently Asked Questions
What is Hookipa Pharma's annual revenue?
Hookipa Pharma (HOOK) reported $43.9M in total revenue for fiscal year 2024. This represents a 118.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Hookipa Pharma's revenue growing?
Hookipa Pharma (HOOK) revenue grew by 118.3% year-over-year, from $20.1M to $43.9M in fiscal year 2024.
Is Hookipa Pharma profitable?
No, Hookipa Pharma (HOOK) reported a net income of -$43.5M in fiscal year 2024, with a net profit margin of -99.0%.
What is Hookipa Pharma's EBITDA?
Hookipa Pharma (HOOK) had EBITDA of -$48.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Hookipa Pharma's operating margin?
Hookipa Pharma (HOOK) had an operating margin of -117.1% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Hookipa Pharma's net profit margin?
Hookipa Pharma (HOOK) had a net profit margin of -99.0% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Hookipa Pharma's return on equity (ROE)?
Hookipa Pharma (HOOK) has a return on equity of -84.9% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Hookipa Pharma's free cash flow?
Hookipa Pharma (HOOK) generated -$77.2M in free cash flow during fiscal year 2024. This represents a -25.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Hookipa Pharma's operating cash flow?
Hookipa Pharma (HOOK) generated -$77.0M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Hookipa Pharma's total assets?
Hookipa Pharma (HOOK) had $82.5M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Hookipa Pharma's capital expenditures?
Hookipa Pharma (HOOK) invested $194K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Hookipa Pharma spend on research and development?
Hookipa Pharma (HOOK) invested $68.5M in research and development during fiscal year 2024.
What is Hookipa Pharma's current ratio?
Hookipa Pharma (HOOK) had a current ratio of 3.27 as of fiscal year 2024, which is generally considered healthy.
What is Hookipa Pharma's debt-to-equity ratio?
Hookipa Pharma (HOOK) had a debt-to-equity ratio of 0.61 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Hookipa Pharma's return on assets (ROA)?
Hookipa Pharma (HOOK) had a return on assets of -52.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Hookipa Pharma's cash runway?
Based on fiscal year 2024 data, Hookipa Pharma (HOOK) had $39.7M in cash against an annual operating cash burn of $77.0M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Hookipa Pharma's Piotroski F-Score?
Hookipa Pharma (HOOK) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Hookipa Pharma's earnings high quality?
Hookipa Pharma (HOOK) has an earnings quality ratio of 1.77x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Hookipa Pharma cover its interest payments?
Hookipa Pharma (HOOK) has an interest coverage ratio of -25727.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Hookipa Pharma?
Hookipa Pharma (HOOK) scores 42 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.